Revolution Medicines (RVMD) Income towards Parent Company (2019 - 2026)

Revolution Medicines' Income towards Parent Company history runs 8 years deep, the most recent figure standing at -$453.8 million for Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 112.64% year-over-year to -$453.8 million in Q1 2026; TTM through Mar 2026 was -$240.4 million, a 65.53% increase from a year earlier, with the FY2024 full-year figure at -$600.0 million, down 36.31% from the prior year.
• Income towards Parent Company retreated to -$453.8 million in Q1 2026 per RVMD's latest filing, from $766.4 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $766.4 million in Q4 2025 and bottomed at -$453.8 million in Q1 2026.
• The 5-year median for Income towards Parent Company is -$116.0 million (2024), against an average of -$102.5 million.
• Across the five-year window, Income towards Parent Company plunged 192.58% in 2023 and jumped 494.0% in 2025, its largest moves.
• Year by year, Income towards Parent Company stood at -$56.5 million in 2022, then tumbled by 192.58% to -$165.4 million in 2023, then decreased by 17.62% to -$194.5 million in 2024, then soared by 494.0% to $766.4 million in 2025, then sank by 159.21% to -$453.8 million in 2026.
• Per Business Quant, the three latest RVMD Income towards Parent Company figures stand at -$453.8 million (Q1 2026), $766.4 million (Q4 2025), and -$305.2 million (Q3 2025).